Full-Time

Vice President

Clinical Development

Posted on 7/26/2024

Lyell Immunopharma

Lyell Immunopharma

201-500 employees

Develops advanced cell therapies for cancer

Biotechnology
Healthcare

Senior

Seattle, WA, USA + 1 more

More locations: San Bruno, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD with 12 years’ experience; MD/PhD a plus; focus in oncology
  • Medically licensed, Fellowship and/or Board certification in oncology, hematology
  • A minimum of 10 years’ experience in clinical development, with substantial experience in the pharmaceutical industry leading successful clinical programs
  • Proven experience in Phase 1 clinical programs
Responsibilities
  • Develop and implement the clinical development strategy for a Program aligned with the company’s overall goals and objectives.
  • Oversee development of clinical development plans (CDPs) and clinical trial protocols.
  • Analyze and interpret clinical trial data including patient data, provide medical direction to teams for execution of protocols, to develop clinical study reports, and in making decisions and/or troubleshooting issues.
  • Oversee the monitoring and reporting of adverse events and safety signals, ensure patient safety and ethical conduct of clinical trials and develop and implement risk management strategies.
  • Ensure the scientific integrity of clinical studies and compliance with regulatory requirements.
  • Collaborate with regulatory affairs to define the regulatory strategy and provide oversight and expertise in the regulatory submission process (IND, BLA, etc.).
  • Ensure adherence to all regulatory guidelines and Good Clinical Practice (GCP) standards.
  • Lead and manage the clinical development team, provide guidance, mentorship, and professional development opportunities.
  • Represent clinical development in executive leadership meetings and contribute to strategic decision-making processes.
  • Serve as a medical representative in meetings with regulatory agencies (e.g., FDA, EMA).
  • Develop and review scientific content for regulatory documents, scientific communications and marketing materials.
  • Provide medical expertise to support product development, marketing, and sales teams.
  • Represent the company at scientific conferences, industry meetings, and in interactions with key opinion leaders (KOLs).

Lyell Immunopharma focuses on developing advanced cell therapies specifically for treating solid tumors, which are cancerous tissue masses. The company utilizes T cells, a type of immune cell, and employs techniques like genetic and epigenetic reprogramming to enhance their effectiveness against cancer. This approach addresses challenges such as T cell exhaustion and the need for T cells to maintain their ability to renew and persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments for solid tumors, with a diverse pipeline of therapies that can be licensed or sold to healthcare providers. The goal is to push the limits of current cancer treatments and provide effective solutions for patients where traditional methods have not succeeded.

Company Stage

IPO

Total Funding

$479.6M

Headquarters

San Francisco, California

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of ImmPACT Bio enhances Lyell's CAR T-cell therapy capabilities.
  • Strategic partnership with MaxCyte boosts cell engineering and therapeutic development.
  • New leadership appointments strengthen Lyell's strategic direction and management.

What critics are saying

  • Increased competition in T-cell therapies may impact Lyell's market share.
  • Delays in clinical data results could lead to investor uncertainty.
  • Integration challenges from ImmPACT Bio acquisition may divert focus from core operations.

What makes Lyell Immunopharma unique

  • Lyell focuses on T cell reprogramming to treat solid tumors effectively.
  • Their proprietary Gen-R and Epi-R platforms address T cell exhaustion and stemness.
  • Lyell's diverse product pipeline explores multiple treatment modalities for solid tumors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Phone/Internet Stipend

INACTIVE